Soriano-Gabarró Montse, Toé Laurent, Tiendrebeogo Sylvestre R M, Nelson Christopher B, Dabal Moumouni, Djingarey Mamoudou H, Plikaytis Brian, Rosenstein Nancy
GlaxoSmithKline (GSK) Biologicals, Rue Institut 89, Rixensart, Belgium.
Vaccine. 2007 Sep 3;25 Suppl 1:A92-6. doi: 10.1016/j.vaccine.2007.04.048. Epub 2007 May 7.
Following a large Neisseria meningitidis W135 (NmW135) epidemic in Burkina Faso (BF) during 2002, a newly licensed trivalent A/C/W135 meningococcal polysaccharide vaccine was introduced in 2003. We conducted a case-control study to assess the vaccine effectiveness (VE) against meningococcal disease. Thirty-two N. meningitidis A (NmA) and 3 NmW135 meningitis cases were enrolled and matched by age-neighborhood to 103 controls. After adjusting for confounding risk factors, VE against NmA or NmW135 was 83.6% (95% CI 31.8-97.0, p=0.01) for persons with verified vaccination. VE against probable/definite NmA alone was 94.0% (95% CI 58.7-99.0, p=0.0003). Low number of NmW135 cases did not allow estimation of VE against NmW135 alone. The vaccine was highly effective against the epidemic. Since 2003, the trivalent vaccine continues to be effectively used in Africa for the control of meningococcal disease epidemics.
2002年布基纳法索（BF）出现大规模的W135群脑膜炎奈瑟菌（NmW135）疫情后，2003年引入了一种新获许可的三价A/C/W135脑膜炎球菌多糖疫苗。我们开展了一项病例对照研究，以评估该疫苗针对脑膜炎球菌病的疫苗效力（VE）。纳入了32例A群脑膜炎奈瑟菌（NmA）和3例NmW135脑膜炎病例，并按年龄-社区与103名对照进行匹配。在对混杂风险因素进行校正后，已证实接种疫苗者针对NmA或NmW135的疫苗效力为83.6%（95%CI 31.8-97.0，p=0.01）。仅针对可能/确诊的NmA的疫苗效力为94.0%（95%CI 58.7-99.0，p=0.0003）。NmW135病例数量较少，无法单独估计针对NmW135的疫苗效力。该疫苗对此次疫情具有高度有效性。自2003年以来，三价疫苗继续在非洲有效用于控制脑膜炎球菌病疫情。
